|
1
|
Linares MA, Zakaria A and Nizran P: Skin
cancer. Prim Care. 42:645–659. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haenssle HA, Mograby N, Ngassa A, Buhl T,
Emmert S, Schön MP, Rosenberger A and Bertsch HP: Association of
patient risk factors and frequency of nevus-associated cutaneous
melanomas. JAMA Dermatol. 152:291–298. 2016. View Article : Google Scholar
|
|
3
|
Tsao H, Chin L, Garraway LA and Fisher DE:
Melanoma: From mutations to medicine. Genes Dev. 26:1131–1155.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moon H, Donahue LR, Choi E, Scumpia PO,
Lowry WE, Grenier JK, Zhu J and White AC: Melanocyte stem cell
activation and translocation initiate cutaneous melanoma in
response to UV exposure. Cell Stem Cell. 21:665–678. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ježek P, Holendová B, Garlid KD and
Jabůrek M: Mitochondrial uncoupling Proteins: Subtle regulators of
cellular redox signaling. Antioxid Redox Signal. 29:667–714. 2018.
View Article : Google Scholar
|
|
6
|
Rial E, González‑Barroso MM, Fleury C and
Bouillaud F: The structure and function of the brown fat uncoupling
protein UCP1: Current status. Biofactors. 8:209–219. 1998.
View Article : Google Scholar
|
|
7
|
Toda C and Diano S: Mitochondrial UCP2 in
the central regulation of metabolism. Best Pract Res Clin
Endocrinol Metab. 28:757–764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boss O, Samec S, Paoloni-Giacobino A,
Rossier C, Dulloo A, Seydoux J, Muzzin P and Giacobino JP:
Uncoupling protein-3: A new member of the mitochondrial carrier
family with tissue‑specific expression. FEBS Lett. 408:39421997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mao W, Yu XX, Zhong A, Li W, Brush J,
Sherwood SW, Adams SH and Pan G: UCP4, a novel brain‑specific
mitochondrial protein that reduces membrane potential in mammalian
cells. FEBS Lett. 443:326–330. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu XX, Mao W, Zhong A, Schow P, Brush J,
Sherwood SW, Adams SH and Pan G: Characterization of novel
UCP5/BMCP1 isoforms and differential regulation of UCP4 and UCP5
expression through dietary or temperature manipulation. FASEB J.
14:1611–1618. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brandi J, Cecconi D, Cordani M,
Torrens-Mas M, Pacchiana R, Dalla Pozza E, Butera G, Manfredi M,
Marengo E, Oliver J, et al: The antioxidant uncoupling protein 2
stimulates hnRNPA2/B1, GLUT1 and PKM2 expression and sensitizes
pancreas cancer cells to glycolysis inhibition. Free Radic Biol
Med. 101:305–316. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Elorza A, Hyde B, Mikkola HK, Collins S
and Shirihai OS: UCP2 modulates cell proliferation through the
MAPK/ERK pathway during erythropoiesis and has no effect on heme
biosynthesis. J Biol Chem. 283:30461–30470. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dando I, Pacchiana R, Pozza ED, Cataldo I,
Bruno S, Conti P, Cordani M, Grimaldi A, Butera G, Caraglia M, et
al: UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH
nuclear translocation in genipin/everolimus anticancer synergism.
Free Radic Biol Med. 113:176–189. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li W, Zhang C, Jackson K, Shen X, Jin R,
Li G, Kevil CG, Gu X, Shi R and Zhao Y: UCP2 knockout suppresses
mouse skin carcinogenesis. Cancer Prev Res (Phila). 8:487–491.
2015. View Article : Google Scholar
|
|
15
|
Sreedhar A, Petruska P, Miriyala S,
Panchatcharam M and Zhao Y: UCP2 overexpression enhanced glycolysis
via activation of PFKFB2 during skin cell transformation.
Oncotarget. 8:95504– 95515. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sreedhar A, Lefort J, Petruska P, Gu X,
Shi R, Miriyala S, Panchatcharam M and Zhao Y: UCP2 upregulation
promotes Plcγ-1 signaling during skin cell transformation. Mol
Carcinog. 56:2290–2300. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rossi S, Cordella M, Tabolacci C, Nassa G,
D'Arcangelo D, Senatore C, Pagnotto P, Magliozzi R, Salvati A,
Weisz A, et al: TNF-alpha and metalloproteases as key players in
melanoma cells aggressiveness. J Exp Clin Cancer Res. 37:3262018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bhatia S, Tykodi SS and Thompson JA:
Treatment of metastatic melanoma: An overview. Oncology (Williston
Park). 23:488–496. 2009.
|
|
19
|
Rofstad EK, Wahl A, Davies Cde L and
Brustad T: Growth characteristics of human melanoma multicellular
spheroids in liquid-overlay culture: Comparisons with the parent
tumour xenografts. Cell Tissue Kinet. 19:205–216. 1986.PubMed/NCBI
|
|
20
|
Bosman FT, de Goeij AF and Rousch M:
Quality control in immunocytochemistry: Experiences with the
oestrogen receptor assay. J Clin Pathol. 45:120–124. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baffy G, Derdak Z and Robson SC:
Mitochondrial recoupling: A novel therapeutic strategy for cancer?
Br J Cancer. 105:469–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gill KS, Fernandes P, O'Donovan TR,
McKenna SL, Doddakula KK, Power DG, Soden DM and Forde PF:
Glycolysis inhibition as a cancer treatment and its role in an
anti-tumour immune response. Biochim Biophys Acta. 1866:87–105.
2016.PubMed/NCBI
|
|
23
|
Pópulo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Calero R, Morchon E, Martinez-Argudo I and
Serrano R: Synergistic anti-tumor effect of 17AAG with the
PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett.
406:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Babchia N, Calipel A, Mouriaux F, Faussat
AM and Mascarelli F: The PI3K/Akt and mTOR/P70S6K signaling
pathways in human uveal melanoma cells: Interaction with B-Raf/ERK.
Invest Ophthalmol Vis Sci. 51:421–429. 2010. View Article : Google Scholar
|
|
26
|
Mao XH, Chen M, Wang Y, Cui PG, Liu SB and
Xu ZY: MicroRNA-21 regulates the ERK/NF-κB signaling pathway to
affect the proliferation, migration, and apoptosis of human
melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN. Mol
Carcinog. 56:886–894. 2017. View
Article : Google Scholar
|
|
27
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eggermont AM, Spatz A and Robert C:
Cutaneous melanoma. Lancet. 383:816–827. 2014. View Article : Google Scholar
|
|
29
|
Rigel DS: Epidemiology of melanoma. Semin
Cutan Med Surg. 29:204–209. 2010. View Article : Google Scholar
|
|
30
|
Li W, Nichols K, Nathan CA and Zhao Y:
Mitochondrial uncoupling protein 2 is up-regulated in human head
and neck, skin, pancreatic, and prostate tumors. Cancer Biomark.
13:377–383. 2013. View Article : Google Scholar
|
|
31
|
Estrada Y, Dong J and Ossowski L: Positive
crosstalk between ERK and p38 in melanoma stimulates migration and
in vivo proliferation. Pigment Cell Melanoma Res. 22:66–76. 2009.
View Article : Google Scholar
|
|
32
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Govindarajan B, Sligh JE, Vincent BJ, Li
M, Canter JA, Nickoloff BJ, Rodenburg RJ, Smeitink JA, Oberley L,
Zhang Y, et al: Overexpression of Akt converts radial growth
melanoma to vertical growth melanoma. J Clin Invest. 117:719–729.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Niessner H, Forschner A, Klumpp B,
Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J,
Tabatabai G, et al: Targeting hyperactivation of the AKT survival
pathway to overcome therapy resistance of melanoma brain
metastases. Cancer Med. 2:76–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cho JH, Robinson JP, Arave RA, Burnett WJ,
Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW,
McMahon M and Holmen SL: AKT1 activation promotes development of
melanoma metastases. Cell Rep. 13:898–905. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dai DL, Martinka M and Li G: Prognostic
significance of activated Akt expression in melanoma: A
clinicopathologic study of 292 cases. J Clin Oncol. 23:1473–1482.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Polivka Jr J and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar
|
|
39
|
Yang Y, Luo Z, Hao Y, Ba W, Wang R, Wang
W, Ding X and Li C: mTOR-mediated Na+/Ca2+ exchange affects cell
proliferation and metastasis of melanoma cells. Biomed
Pharmacother. 92:744–749. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sinnberg T, Lasithiotakis K, Niessner H,
Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J,
Garbe C and Meier F: Inhibition of PI3K-AKT-mTOR signaling
sensitizes melanoma cells to cisplatin and temozolomide. J Invest
Dermatol. 129:1500–1515. 2009. View Article : Google Scholar
|
|
41
|
Yu X, Luo A, Liu Y, Wang S, Li Y, Shi W,
Liu Z and Qu X: MiR-214 increases the sensitivity of breast cancer
cells to tamoxifen and fulvestrant through inhibition of autophagy.
Mol Cancer. 14:2082015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Szatrowski TP and Nathan CF: Production of
large amounts of hydrogen peroxide by human tumor cells. Cancer
Res. 51:794–798. 1991.PubMed/NCBI
|
|
43
|
Lisanti MP, Martinez-Outschoorn UE, Lin Z,
Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A and Sotgia F:
Hydrogen peroxide fuels aging, inflammation, cancer metabolism and
metastasis: The seed and soil also needs 'fertilizer'. Cell Cycle.
10:2440–2449. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cheng WC, Tsui YC, Ragusa S, Koelzer VH,
Mina M, Franco F, Läubli H, Tschumi B, Speiser D, Romero P, et al:
Uncoupling protein 2 reprograms the tumor microenvironment to
support the anti-tumor immune cycle. Nat Immunol. 20:206–217. 2019.
View Article : Google Scholar : PubMed/NCBI
|
